Ralmitaront

Last updated
Ralmitaront
Ralmitaront.svg
Clinical data
Other namesRG-7906; RG7906; RO-6889450; RO6889450
Identifiers
  • 5-Ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C17H22N4O2
Molar mass 314.389 g·mol−1
3D model (JSmol)
  • CCC1=C(C(=NN1)C(=O)NC2=CC=C(C=C2)[C@H]3CNCCO3)C
  • InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1
  • Key:XHHXGKRFUPEPFM-OAHLLOKOSA-N

Ralmitaront (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which was undergoing a Phase II clinical trial for the treatment of negative symptoms in schizophrenia and schizoaffective disorder, but the trial was discontinued due to lack of efficacy. [1] [2] [3] [4] Another Phase II clinical trial targeting acute psychotic symptoms of schizophrenia was also terminated for the same reason. [5] It is a partial agonist of the TAAR1 protein. [6] The medication is being developed by the pharmaceutical company Hoffmann-La Roche. [1] Ralmitaront had completed Phase I clinical trials. [1] [7]

See also

References

  1. 1 2 3 "Ralmitaront - Roche". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Gomes FV, Grace AA (April 2021). "Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention". International Journal of Molecular Sciences. 22 (9): 4467. doi: 10.3390/ijms22094467 . PMC   8123139 . PMID   33922888.
  3. ↑ Clinical trial number NCT04512066 for "Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms" at ClinicalTrials.gov
  4. ↑ "Roche Terminates Second Phase II Schizophrenia Trial". BioSpace. 2023-05-23. Retrieved 2025-04-06.
  5. ↑ Clinical trial number NCT03669640 for "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder" at ClinicalTrials.gov
  6. ↑ "Ralmitaront: Relationships: Trace Amine-Associated Receptor 1". Global Substance Registration System (GSRS). U.S. Food and Drug Administration.
  7. ↑ Clinical trial number NCT02699372 for "The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers" at ClinicalTrials.gov


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.